This study investigates the use of an imaging drug to evaluate breast cancer that has spread to other parts of the body, known as metastatic breast cancer. The purpose of this study is to see if the imaging drug can help predict how well the cancer responds to therapy. Metastatic means the cancer has moved from its original location to other parts of the body.

In this study, participants will undergo positron emission tomography (PET) and computed tomography (CT) scans. These scans are special types of imaging that allow doctors to see inside the body and evaluate the cancer. The study uses a specific imaging drug that is not yet approved by the FDA to see if it can be effective in predicting treatment responses.

• Who can participate: Participants must be adults diagnosed with metastatic breast cancer. Additional eligibility criteria include specific health conditions and prior treatment history.
• Study details: Participants will receive PET, a type of scan that shows how tissues and organs are functioning, and CT, a type of scan that provides detailed images of internal organs, using an investigational imaging drug. These scans aim to determine how the cancer is responding to treatment. The imaging drug is not yet approved by the FDA.